SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Oncternal Therapeutics, Inc. (ONCT) .
本页证实的标准:
- VALUE (100/100, 通过) — 分析师目标价暗示上行空间 (+5217.1%).
- 分析师共识目标价 $28.00 (+5217.1% 上行空间) — 华尔街分析师认为存在显著上行潜力。
SharesGrow 综合评分： 41/100 其中 3/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
100/100
Price-to-Earnings & upside
Proven by this page
✓
健康
100/100
Debt-to-Equity & liquidity
→ Health
估值概览 — ONCT
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率1.97
EV/EBITDA0.0
每股数据
EPS (TTM)$-13.43
每股账面价值$0.00
每股营收$0.27
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
分析师目标价$28.00 (+5217.1%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2014 |
$-33.72 |
$0.00 |
$-39.41M |
- |
| 2015 |
$-8.86 |
$0.00 |
$-18.7M |
- |
| 2016 |
$-8.52 |
$-2.51M |
$-17.72M |
- |
| 2017 |
$-12.22 |
$1.67M |
$-30.44M |
-1818.3% |
| 2018 |
$-11.52 |
$2.52M |
$-38.42M |
-1523.9% |
| 2019 |
$-30.81 |
$2.43M |
$-15.91M |
-656.2% |
| 2020 |
$-16.95 |
$3.38M |
$-17.21M |
-509.9% |
| 2021 |
$-12.69 |
$4.32M |
$-31.3M |
-725.4% |
| 2022 |
$-16.50 |
$1.49M |
$-43.39M |
-2912.3% |
| 2023 |
$-13.43 |
$785K |
$-39.48M |
-5029.2% |
